CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
Key Highlights
- ➤Sarborg files patent covering novel solid forms of a first-in-class respiratory medicine
- ➤CDT holds 1,290 Sarborg shares, representing 22.7% of issued share capital
- ➤Sarborg’s latest capital raise valued CDT’s holding at approximately $161 million
- ➤Target respiratory treatment market estimated at more than $20 billion annually
- ➤Sarborg plans characterization and early in-vitro studies to support licensing discussions
Expert Statements
James Bligh, Chief Executive Officer of CDT
“Sarborg has now built a valuable portfolio of patented solid-form assets, and this filing strengthens its asset base and its prospects as it builds a data package to support licensing and partnership discussions,”
James Bligh, Chief Executive Officer of CDT
“As a significant shareholder in Sarborg, CDT is encouraged by the continued growth of Sarborg’s IP portfolio.”
Dr. Andrew Regan, Chief Executive Officer of Sarborg
“This is one of the most significant filings in Sarborg’s portfolio to date,”
Dr. Andrew Regan, Chief Executive Officer of Sarborg
“We have secured novel solid forms of a first-in-class medicine with enormous potential, forms we did not expect to find, and our agentic and quantum models have already mapped where that potential could be realized.”
Dr. Andrew Regan, Chief Executive Officer of Sarborg
“We believe this creates a compelling opportunity for the asset and for Sarborg.”
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 14, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company") today notes the announcement from Sarborg Limited regarding intellectual property covering novel solid forms of a major, first-in-class respiratory medicine, an asset class addressing a treatment market estimated at more than $20 billion annually.
“Sarborg has now built a valuable portfolio of patented solid-form assets, and this filing strengthens its asset base and its prospects as it builds a data package to support licensing and partnership discussions,” said James Bligh, Chief Executive Officer of CDT. “As a significant shareholder in Sarborg, CDT is encouraged by the continued growth of Sarborg’s IP portfolio.”
Get started
Create a free account to read the full story.